Jura Bio is a therapeutics company focused on translating successes in CAR-T to autoimmune disorders.
JURA Bio has raised $16.1M in total funding. The most recent round was Seed. The last funding was announced in September 2023.
JURA Bio's investors include John Ballantyne, Fontus Capital, Michael Chambers, Josh Ellington.
JURA Bio is headquartered in Somerville, United States.
Jura Bio is a therapeutics company focused on translating successes in CAR-T to autoimmune disorders.
JURA Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"JURA Bio — Funding & Investors." VCBacked, September 21, 2023, https://www.vcbacked.co/company/jura-bio. Accessed September 14, 2026.
VCBacked. (2023). JURA Bio — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/jura-bio
{{cite web |title=JURA Bio — Funding & Investors |url=https://www.vcbacked.co/company/jura-bio |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated